---
title: "Aprea Therapeutics Inc 預計每股將虧損 34 美分 - 財報預覽"
description: "Aprea Therapeutics Inc 預計在截至 2025 年 9 月 30 日的季度報告每股虧損 34 美分，預計收入將下降。分析師維持 “強烈買入” 評級，沒有持有或賣出的建議。12 個月的中位數目標價為 10.50 美元，比最後的收盤價 1.40 美元上漲 86.7%。過去三個月的平均盈利預期保持不變"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/264049725.md"
published_at: "2025-11-03T14:40:19.000Z"
---

# Aprea Therapeutics Inc 預計每股將虧損 34 美分 - 財報預覽

> Aprea Therapeutics Inc 預計在截至 2025 年 9 月 30 日的季度報告每股虧損 34 美分，預計收入將下降。分析師維持 “強烈買入” 評級，沒有持有或賣出的建議。12 個月的中位數目標價為 10.50 美元，比最後的收盤價 1.40 美元上漲 86.7%。過去三個月的平均盈利預期保持不變

-   Aprea Therapeutics Inc 預計在 2025 年 9 月 30 日結束的季度報告中，季度收入將出現下降，預計於 11 月 5 日公佈結果。
-   LSEG 對 Aprea Therapeutics Inc 的平均分析師預期為每股虧損 34 美分。
-   當前對該股票的平均分析師評級為 “強烈買入”，推薦的細分為 2 個 “強烈買入” 或 “買入”，沒有 “持有”，也沒有 “賣出” 或 “強烈賣出”。
-   分析師的平均盈利預期在過去三個月內沒有變化。
-   華爾街對 Aprea Therapeutics Inc 的 12 個月中位數目標價為 10.50 美元，約比其最後收盤價 1.40 美元高出 86.7%。

### Related Stocks

- [APRE.US - Aprea Therapeutics](https://longbridge.com/zh-HK/quote/APRE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars | Aprea Therapeutics shares surged 16.62% to $0.70 following promising Phase 1 trial results for APR-1051, a WEE1 kinase i | [Link](https://longbridge.com/zh-HK/news/276264904.md) |
| Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio | Aprea Therapeutics has secured new patents in Australia and Japan, enhancing its global intellectual property for its DN | [Link](https://longbridge.com/zh-HK/news/275688060.md) |
| Aprea Therapeutics CFO John P. Hamill Acquires Common Shares | John P. Hamill, CFO of Aprea Therapeutics Inc., has acquired common shares of the company. The full filing is available  | [Link](https://longbridge.com/zh-HK/news/274557772.md) |
| Aprea Therapeutics Raises $3.1 Million in Private Placement | Aprea Therapeutics Inc. announced a $3.1 million private placement, selling shares and warrants at $1.165 each, exercisa | [Link](https://longbridge.com/zh-HK/news/269093424.md) |
| Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers | Aprea Therapeutics Inc. has provided updates on its clinical trials for APR-1051 and ATRN-119. In the Phase 1 trial of A | [Link](https://longbridge.com/zh-HK/news/265540377.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。